Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.07 (-8.12%)
Close on Nov 12, 2026Market cap $285.72MP/E –Yield 0.00%
Allogene Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Allogene Therapeutics's operating margin for the twelve months ending Dec 31, 2024 was -1241813.6%. For fiscal 2024 it was -1241813.6%, against -344986.3% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -1241813.6% | −896827.3 |
| FY2023 | Dec 31, 2023 | -344986.3% | −129899.1 |
| FY2022 | Dec 31, 2022 | -215087.2% | −214929.2 |
| FY2021 | Dec 31, 2021 | -157.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1011.2% | +365079.7 |
| Q1 FY2024 | Mar 31, 2024 | -315927.3% | +14379.4 |
| Q4 FY2023 | Dec 31, 2023 | -405281.0% | −34531.0 |
| Q3 FY2023 | Sep 30, 2023 | -286345.5% | +19250.8 |
| Q2 FY2023 | Jun 30, 2023 | -366090.9% | −246378.4 |
| Q1 FY2023 | Mar 31, 2023 | -330306.7% | −125142.6 |
| Q4 FY2022 | Dec 31, 2022 | -370750.0% | −370752.3 |
| Q3 FY2022 | Sep 30, 2022 | -305596.3% | −147086.1 |
| Q2 FY2022 | Jun 30, 2022 | -119712.5% | +41717.0 |
| Q1 FY2022 | Mar 31, 2022 | -205164.1% | −205077.5 |
| Q4 FY2021 | Dec 31, 2021 | 2.3% | – |
| Q3 FY2021 | Sep 30, 2021 | -158510.2% | – |
| Q2 FY2021 | Jun 30, 2021 | -161429.5% | – |
| Q1 FY2021 | Mar 31, 2021 | -86.6% | – |
See a number that looks wrong?